Victor T Chang1, Charles B Scott2, Melanie L Gonzalez3, Jan Einhorn3, Houling Yan4, Basil S Kasimis5. 1. Section Hematology Oncology (111), VA New Jersey Health Care System, East Orange, New Jersey, USA; Department of Medicine, Rutgers New Jersey Medical School, Newark, New Jersey, USA. Electronic address: Victor.chang@va.gov. 2. CBS Squared, Inc., Fort Washington, Pennsylvania, USA. 3. Section Hematology Oncology (111), VA New Jersey Health Care System, East Orange, New Jersey, USA. 4. Veterans Biomedical Research Institute, VA New Jersey Health Care System, East Orange, New Jersey, USA. 5. Section Hematology Oncology (111), VA New Jersey Health Care System, East Orange, New Jersey, USA; Department of Medicine, Rutgers New Jersey Medical School, Newark, New Jersey, USA.
Abstract
CONTEXT: Physicians overestimate survival in patients with advanced cancer. Patient-reported outcomes could provide another way to estimate survival. We previously reported four prognostic groups based on Karnofsky Performance Status, Functional Assessment of Cancer Therapy physical well-being subscale, and Memorial Symptom Assessment Scale-Short Form physical symptom distress subscale scores. OBJECTIVES: To determine the validity of these four prognostic groups. METHODS: We performed prospective surveys. Data from a total of 880 Veterans Affairs Medical Center patients, 417 in the First Cohort and 463 in the Validation Cohort, were analyzed. Both inpatients and outpatients were prospectively recruited in Institutional Review Board-approved studies from August 1999 to September 2009. Survival was measured from the date of entry until death or December 1, 2009. Patients completed self-assessments with the Functional Assessment of Cancer Therapy and Memorial Symptom Assessment Scale-Short Form. Analysis of variance was used to test differences between groups in continuous variables; a generalized Wilcoxon test was used for differences between groups for survival. RESULTS: The average age in the Validation Cohort was 66.5 years and 98% were men. The majority of patients had metastatic cancer (90%), with lung (28%) and prostate (26%) cancers being predominant. The median Karnofsky Performance Status was 70. Median survival was 33, 46.5, 124, and 209.5 days for the four prognostic groups (P < 0.0001, all pair-wise comparisons P < 0.02). CONCLUSION: The four prognostic groups remained distinct in the prospective cohort. Small differences in patient-reported physical well-being can halve survival estimates. Patient-reported outcomes can correct for physician overestimate of prognosis. This study provides a way to use patient-reported outcomes for prognosis in patients with advanced cancer, with important implications for assessment. Published by Elsevier Inc.
CONTEXT: Physicians overestimate survival in patients with advanced cancer. Patient-reported outcomes could provide another way to estimate survival. We previously reported four prognostic groups based on Karnofsky Performance Status, Functional Assessment of Cancer Therapy physical well-being subscale, and Memorial Symptom Assessment Scale-Short Form physical symptom distress subscale scores. OBJECTIVES: To determine the validity of these four prognostic groups. METHODS: We performed prospective surveys. Data from a total of 880 Veterans Affairs Medical Center patients, 417 in the First Cohort and 463 in the Validation Cohort, were analyzed. Both inpatients and outpatients were prospectively recruited in Institutional Review Board-approved studies from August 1999 to September 2009. Survival was measured from the date of entry until death or December 1, 2009. Patients completed self-assessments with the Functional Assessment of Cancer Therapy and Memorial Symptom Assessment Scale-Short Form. Analysis of variance was used to test differences between groups in continuous variables; a generalized Wilcoxon test was used for differences between groups for survival. RESULTS: The average age in the Validation Cohort was 66.5 years and 98% were men. The majority of patients had metastatic cancer (90%), with lung (28%) and prostate (26%) cancers being predominant. The median Karnofsky Performance Status was 70. Median survival was 33, 46.5, 124, and 209.5 days for the four prognostic groups (P < 0.0001, all pair-wise comparisons P < 0.02). CONCLUSION: The four prognostic groups remained distinct in the prospective cohort. Small differences in patient-reported physical well-being can halve survival estimates. Patient-reported outcomes can correct for physician overestimate of prognosis. This study provides a way to use patient-reported outcomes for prognosis in patients with advanced cancer, with important implications for assessment. Published by Elsevier Inc.
Entities:
Keywords:
Functional Assessment of Cancer Therapy; Karnofsky Performance Status; Memorial Symptom Assessment Scale-Short Form; Prognosis; quality of life; recursive partitioning algorithm; survival; symptoms
Authors: Ilufredo Y Tantoy; Anand Dhruva; Janine Cataldo; Alan Venook; Bruce A Cooper; Steven M Paul; Jon D Levine; Yvette P Conley; Frances Cartwright; Kathryn Lee; Fay Wright; Christine Miaskowski Journal: J Gastrointest Oncol Date: 2017-02
Authors: F T Roncolato; E Gibbs; C K Lee; R Asher; L C Davies; V J Gebski; M Friedlander; F Hilpert; L Wenzel; M R Stockler; M King; E Pujade-Lauraine Journal: Ann Oncol Date: 2017-08-01 Impact factor: 32.976